Asco 2021 – Abstract lift drives first stock moves
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
Asco 2021 – off-the-shelf cell therapy inches towards reality
After years of waiting, courtesy of Allogene investors at last have an allogeneic Car-T dataset comparable with autologous therapies.
Asco 2021 – adjuvant lung cancer beckons for Tecentriq, but only in PD-L1 expressers
Impower-010 scores on an apparently approvable endpoint, but the effect in all-comers is illusory, researchers reckon.
Asco 2021 – Adaptimmune’s T-cell receptors see a route to market
The registrational Spearhead-1 trial of afami-cel backs up the efficacy seen in phase 1, without some of the related toxicities.
Asco 2021 – Bristol’s Lag3 case for a replacement for Yervoy
The Relativity-047 study shows that relatlimab has a big safety advantage over Yervoy, with just a slight decrease in clinical benefit.
ACC 2021 – Esbriet could Pirouette into heart failure
The IPF drug shows surprising promise in heart failure with preserved ejection fraction.
EHA 2021 – Curis’s renaissance continues
Results in a handful of patients raise hopes again for Curis's blood cancer project CA-4948, but it is still early days.
Validation for a drug class, and for Sanofi
If imminent results of Sanofi’s amcenestrant in Ameera-3 are positive Serds could finally see late-stage validation.
